Clinical Trial: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Study Status: Completed
Recruit Status: RECRUITING
Condition: Acute Myeloid Leukemia
Study Type: INTERVENTIONAL
Official Title: An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD
Brief Summary:
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
Read more